Merck has filed a patent infringement suit against Impax Laboratories after the generic-drug maker applied for FDA approval of a generic version of the blockbuster cholesterol drug Vytorin. The suit was lodged in response to Impax’s recently filed ANDA for generic Vytorin (ezetimibe/simvastatin) that contained a Paragraph IV certification challenging the validity of the ’721 and ’966 patents on the drug, Merck says in its complaint filed recently in a New Jersey federal court.
Generic Line